Literature DB >> 3125258

Benzoquinone activation of Cryptococcus neoformans capsular polysaccharide for construction of an immunoaffinity column.

T R Kozel1, C A Hermerath.   

Abstract

p-benzoquinone was used as a two-step coupling reagent for preparation of an immunoaffinity absorbent in which the capsular polysaccharide of Cryptococcus neoformans was linked to an agarose gel. Cryptococcal polysaccharide is a difficult subject for chemical modification because it contains immunogenic O-acetyl groups which are sensitive to alkaline hydrolysis. The polysaccharide was activated by treatment with benzoquinone. The 'activated' polysaccharide was reactive with amino groups on AH-Sepharose. A pH of 8-9 was optimal for activation of the polysaccharide. Once activated, the polysaccharide was reactive with a model substrate, L-alanine-4-nitroanilide, over a pH range of 6-10. Since the O-acetyl groups are hydrolyzed at pH above 8.0, an activation pH of 8.0 and a coupling pH of 7.5 were used to prepare the conjugated gel. The polysaccharide immunoaffinity column was used successfully for isolation of rabbit antibodies to cryptococcal polysaccharide.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3125258     DOI: 10.1016/0022-1759(88)90008-7

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  11 in total

1.  Capsular reactions of Cryptococcus neoformans with polyspecific and oligospecific polyclonal anticapsular antibodies.

Authors:  T C MacGill; R S MacGill; T R Kozel
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

2.  Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide.

Authors:  J E Sanford; D M Lupan; A M Schlageter; T R Kozel
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

3.  Complement component 3 binding to Haemophilus influenzae type b in the presence of anticapsular and anti-outer membrane antibodies.

Authors:  S V Hetherington; C C Patrick
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

4.  Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule.

Authors:  T R Kozel; B C deJong; M M Grinsell; R S MacGill; K K Wall
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

5.  Antigenic and biological characteristics of mutant strains of Cryptococcus neoformans lacking capsular O acetylation or xylosyl side chains.

Authors:  Thomas R Kozel; Stuart M Levitz; Françoise Dromer; Marcellene A Gates; Peter Thorkildson; Guilhem Janbon
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

6.  Fc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificity.

Authors:  Dale Netski; Thomas R Kozel
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

7.  Opsonization of Cryptococcus neoformans by a family of isotype-switch variant antibodies specific for the capsular polysaccharide.

Authors:  A M Schlageter; T R Kozel
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

8.  Acute lethal toxicity following passive immunization for treatment of murine cryptococcosis.

Authors:  A C Savoy; D M Lupan; P B Manalo; J S Roberts; A M Schlageter; L C Weinhold; T R Kozel
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

9.  Contribution of murine IgG Fc regions to antibody binding to the capsule of Burkholderia pseudomallei.

Authors:  Michael J Dillon; Rachael A Loban; Dana E Reed; Peter Thorkildson; Kathryn J Pflughoeft; Sujata G Pandit; Paul J Brett; Mary N Burtnick; David P AuCoin
Journal:  Virulence       Date:  2016-04-20       Impact factor: 5.882

10.  Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan.

Authors:  A Casadevall; M DeShaw; M Fan; F Dromer; T R Kozel; L A Pirofski
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.